Search results for "obesity drug"

To Curb GLP-1 Misuse, Experts Urge Tracking Who Gets Prescribed Wegovy and Mounjaro—and Why

To Curb GLP-1 Misuse, Experts Urge Tracking Who Gets Prescribed Wegovy and Mounjaro—and Why

As the adoption of GLP-1 receptor agonist obesity medications such as Wegovy and Mounjaro accelerates, medical experts are calling for structured...
Kyungdong Pharmaceutical and AUL Bio Seek Phase 1 Approval for Once-Monthly Obesity Drug AUL009

Kyungdong Pharmaceutical and AUL Bio Seek Phase 1 Approval for Once-Monthly Obesity Drug AUL009

Kyungdong Pharmaceutical announced Sept. 2 that it has submitted an investigational new drug application to the Ministry of Food and Drug Safety for...
Hanmi Pharmaceutical Nears Korean Launch for Obesity Drug EPPE After Five-Year Detour

Hanmi Pharmaceutical Nears Korean Launch for Obesity Drug EPPE After Five-Year Detour

Licensed out to French pharmaceutical giant Sanofi in 2015 and returned five years later, Hanmi Pharmaceutical’s...
Do Wegovy and Mounjaro Count as Doping? WADA Monitors GLP-1 Drugs in Sports

Do Wegovy and Mounjaro Count as Doping? WADA Monitors GLP-1 Drugs in Sports

GLP-1 (glucagon-like peptide-1) class medications, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, are...
Hanmi Licenses Muscle-Preserving Obesity Drug Candidate to Genentech in $2.3 Billion Deal

Hanmi Licenses Muscle-Preserving Obesity Drug Candidate to Genentech in $2.3 Billion Deal

Hanmi Pharmaceutical has entered into an exclusive global licensing agreement with Genentech, a member of the Roche...
JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide

JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide

JW Pharmaceutical announced on Aug. 18 that it has submitted an Investigational New Drug application to South Korea’s...
Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival

Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival

Olix announced on July 30 that its obesity drug candidate, "OLX501A," significantly outperformed a global rival...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven

Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven

Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market

Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market

The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly...
Maximizing Weight Loss vs. Protecting the Heart: The Paradox of Modern Anti-Obesity Drugs

Maximizing Weight Loss vs. Protecting the Heart: The Paradox of Modern Anti-Obesity Drugs

As global demand for anti-obesity medications surges, a fierce pharmaceutical race is underway to develop...